Genetic prodrug activation therapy

被引:26
|
作者
Rigg, A
Sikora, K
机构
[1] ICRF Molecular Oncology Unit, Imperial College of Medicine, Hammersmith Hospital, London W12 0NN, Du Cane Road
来源
MOLECULAR MEDICINE TODAY | 1997年 / 3卷 / 08期
关键词
D O I
10.1016/S1357-4310(97)01082-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Genetic prodrug activation therapy shows promise as a therapeutic option for the treatment of cancer as well as a variety of other diseases. it involves the insertion of a gene encoding a drug-metabolizing enzyme into cells and the systemic administration of a prodrug. The prodrug is converted to a cytotoxic agent by the action of the expressed enzyme. To ensure that the enzyme is only expressed in the targeted subset of cells, the transcriptional apparatus of a gene that is unique to this subset is used to regulate the gene encoding the drug-metabolizing enzyme. As with all types of gene therapy, one of the major obstacles to successful clinical treatment is the development of safe and effective gene delivery systems.
引用
收藏
页码:359 / 366
页数:8
相关论文
共 50 条
  • [41] Prodrug cancer gene therapy
    Altaner, Cestmir
    CANCER LETTERS, 2008, 270 (02) : 191 - 201
  • [42] Fibroblast activation protein alpha (FAP): targeting the reactive stroma as a novel prodrug therapy for cancer
    Brennen, W. Nathaniel
    Rosen, D. Marc
    Denmeade, Samuel R.
    CLINICAL & EXPERIMENTAL METASTASIS, 2011, 28 (02) : 206 - 206
  • [43] Radiation-induced prodrug activation: extending combined modality therapy for some solid tumours
    Nicola J. Farrer
    Geoff S. Higgins
    Ian H. Kunkler
    British Journal of Cancer, 2022, 126 : 1241 - 1243
  • [44] Prodrug-Based Nanoreactors with Tumor-Specific In Situ Activation for Multisynergistic Cancer Therapy
    Ren, Cui
    Liu, Huifang
    Lv, Fangfang
    Zhao, Wencong
    Gao, Shutao
    Yang, Xinjian
    Jin, Yi
    Tan, Yanli
    Zhang, Jinchao
    Liang, Xing-Jie
    Li, Zhenhua
    ACS APPLIED MATERIALS & INTERFACES, 2020, 12 (31) : 34667 - 34677
  • [45] Hybrid Prodrug Nanoparticles with Tumor Penetration and Programmed Drug Activation for Enhanced Chemoresistant Cancer Therapy
    Zhao, Caiyan
    Shao, Leihou
    Lu, Jianqing
    Deng, Xiongwei
    Tong, Yujia
    Wu, Yan
    ACS APPLIED MATERIALS & INTERFACES, 2017, 9 (22) : 18450 - 18461
  • [46] Prodrug activation therapy kills prostate cancer cells in a three-dimensional culture model
    Foley, R.
    Marignol, L.
    Lawler, M.
    BJU INTERNATIONAL, 2007, 100 : 24 - 24
  • [47] Novel prodrug enzyme-activation gene therapy for cancer using methionine γ-lyase and selenomethionine
    Miki, K
    Gupta, A
    Al-Refaie, W
    Xu, M
    Tan, Y
    Bouvet, M
    Chishima, T
    Shimada, H
    Makuuchi, M
    Moossa, AR
    Hoffman, RM
    CANCER GENE THERAPY, 1999, 6 (06) : S21 - S21
  • [48] Nitroaryl phosphoramides as novel prodrugs for E-coli nitroreductase activation in enzyme prodrug therapy
    Hu, LQ
    Yu, CZ
    Jiang, YY
    Han, JY
    Li, ZR
    Browne, P
    Race, PR
    Knox, RJ
    Searle, PF
    Hyde, EI
    JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (23) : 4818 - 4821
  • [49] Radiation-induced prodrug activation: extending combined modality therapy for some solid tumours
    Farrer, Nicola J.
    Higgins, Geoff S.
    Kunkler, Ian H.
    BRITISH JOURNAL OF CANCER, 2022, 126 (09) : 1241 - 1243
  • [50] Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy
    Danks, MK
    Morton, CL
    Krull, EJ
    Cheshire, PJ
    Richmond, LB
    Naeve, CW
    Pawlik, CA
    Houghton, PJ
    Potter, PM
    CLINICAL CANCER RESEARCH, 1999, 5 (04) : 917 - 924